Erythropoietin and Platelet Activation Markers

Phase 4 Completed 12 enrolled Medical University of Vienna

Non-randomizedSingle-groupOpen-labelBasic science

Summary

We hypothesized that the effect of erythropoietin may be reflected by changes in thromboxane B2 (TXB2) and endothelial cell function. Six male and six female subjects received recombinant human epoetin alpha (Erypo®) intravenously (300 Units per kg). Biomarker levels were assessed at baseline and 4, 24, 48 and 72 hours after administration.

Timeline

Start: 2006-11
Primary completion: 2007-02
Completion: 2007-07

Publications

Heinisch BB, Vcelar B, Kapiotis S, Blann A, Wolzt M, Siller-Matula JM, Jilma B. The effect of erythropoietin on platelet and endothelial activation markers: a prospective trial in healthy volunteers. Platelets. 2012;23(5):352-8. doi: 10.3109/09537104.2011.631621. Epub 2011 Nov 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	epoetin alfa	Protein / enzyme biologic	300 iu/kg	Intravenous

Erythropoietin and Platelet Activation Markers

Summary

Timeline

Publications

Drugs

Indications